New Blood-Clotting Disorder Linked to Antibodies
-
by Kerri Miller
February 14, 2025
-
3 min
5 Key Takeaways
-
1
VITT-like MGTS is linked to monoclonal antibodies targeting platelet factor
-
2
It resists standard anticoagulation therapy and features recurring blood clots with low levels of M proteins.
-
3
The study documented distinct molecular characteristics.
-
4
Treatment strategies beyond anticoagulation alone are recommended for these challenging cases.
-
5
Testing for both anti-PF4 antibodies and M proteins is emphasized in unexplained chronic prothrombotic disorders.
A newly identified chronic blood-clotting disorder known as VITT-like monoclonal gammopathy of thrombotic significance (VITT-like MGTS) has been linked to monoclonal antibodies targeting platelet factor 4. The chronic condition resists standard anticoagulation therapy and is characterized by recurring blood clots with low levels of M proteins. The study documented distinct molecular characteristics, emphasizing the importance of testing for both anti-PF4 antibodies and M proteins in unexplained chronic prothrombotic disorders. Treatment strategies beyond anticoagulation alone are recommended for these challenging cases.
Listen Tab content
